New Drug for Recurrent Ovarian Cancer After Chemotherapy
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of high-grade serous or endometrioid ovarian cancer (or related cancer in the peritoneum or fallopian tube)
- Cancer returned or worsened at least 6 months after your first chemotherapy ended (meaning it is 'platinum-sensitive')
- If your cancer has a BRCA gene mutation or HRD deficiency, you must have already received PARP inhibitor maintenance therapy
- Measurable tumors visible on scans at the start of the study
- Good overall health and physical condition (able to care for yourself with minimal help)
- Willing to provide a tumor sample for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug called Rina-S with standard care to see if it helps keep ovarian cancer from coming back. It is for people who have finished their first round of platinum-based chemotherapy and are in remission or stable.
This trial tests whether adding Rina-S to standard maintenance therapy helps prevent cancer from returning in people with recurrent platinum-sensitive ovarian cancer who have responded to second-line platinum-based chemotherapy.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a new experimental drug (JPI-547) combined with bevacizumab (a targeted therapy) as maintenance treatment for recurrent ovarian cancer after initial response to platinum-based chemo. The goal is to see if this combination can keep the cancer from growing longer than standard care.
Hear when a new Platinum-sensitive Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.